NewAmsterdam Pharma Company N.V. Ordinary Shares

NAMSNASDAQ • USD
22.27 USD
↘ 0.53 (2.32%)AT CLOSE (03:59 PM EDT)
21.75
↘ 0.52 (2.35%)
POST MARKET (AS OF 04:18 PM EDT)
Post Market
AS OF 04:18 PM EDT
21.75
↘ 0.52 (2.35%)
🟢Market: OPEN

Shares of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) are trading at $21.75. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, NAMS is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Oct 5, 2026.

Open?$23.06
High?$23.11
Low?$21.44
Prev. Close?$22.80
Volume?1.3M
Avg. Volume?1.7M
VWAP?$21.94
Rel. Volume?0.75x
Bid / Ask
Bid?$18.07 × 100
Ask?$25.14 × 100
Spread?$7.07
Midpoint?$21.61
Valuation & Ratios
Market Cap?2.7B
Shares Out?119.5M
Float?67.3M
Float %?56.3%
P/E Ratio?N/A
P/B Ratio?4.32
EPS?-$2.17
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Employees
100
Market Cap
2.7B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2022-11-23
Address
GOOIMEER 2-35
NARRDEN, P7 1411 DC
Phone: 35 206 2971
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
14
Short Sent.?
35
Piotroski F-Score?0/9Weak
Altman Z-Score?20.52Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?23.28%Squeeze Risk
Short Interest?15.7M
Days to Cover?9.9
Free Float67.3M
Avg Daily Volume1.6M
Settlement Date2026-09-15
Financial Health
Current Ratio?9.03Strong
Quick Ratio?9.03Strong
Cash Ratio?5.81Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
42
4.32FAIR▾
P/S?
Peers
100
S&P
3
382.73HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-9.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
323.17HIGH▾
Returns & Efficiency
ROE?
S&P
3
-41.1%WEAK▾
ROA?
S&P
3
-36.8%WEAK▾
Cash Flow & Enterprise
FCF?$-143722000
Enterprise Value?$2.3B
Fundamentals ratios updated end of day